193 related articles for article (PubMed ID: 26650379)
1. Polycythemia is associated with bone loss and reduced osteoblast activity in mice.
Oikonomidou PR; Casu C; Yang Z; Crielaard B; Shim JH; Rivella S; Vogiatzi MG
Osteoporos Int; 2016 Apr; 27(4):1559-1568. PubMed ID: 26650379
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
[TBL] [Abstract][Full Text] [Related]
4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
6. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
Thurmes PJ; Steensma DP
Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
[TBL] [Abstract][Full Text] [Related]
8. The utility of testing erythropoietin level in polycythemia diagnosis.
Ismail A; Abdalla E; Aqel A; Fadul A; Ahmed A; Alsayed A; Musa M; Yassin MA
Hematology; 2023 Dec; 28(1):2269510. PubMed ID: 37843428
[TBL] [Abstract][Full Text] [Related]
9. The role of a low erythropoietin level for the polycythemia vera diagnosis.
Lupak O; Han X; Xie P; Mahmood S; Mohammed H; Donthireddy V
Blood Cells Mol Dis; 2020 Feb; 80():102355. PubMed ID: 31525610
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin directly stimulates osteoclast precursors and induces bone loss.
Hiram-Bab S; Liron T; Deshet-Unger N; Mittelman M; Gassmann M; Rauner M; Franke K; Wielockx B; Neumann D; Gabet Y
FASEB J; 2015 May; 29(5):1890-900. PubMed ID: 25630969
[TBL] [Abstract][Full Text] [Related]
11. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of beta-2 microglobulin, erythropoietin and tobacco use in polycythemic cases.
Mahe K; Couturaud F; Kerspern H; Chauveau A; Ianotto JC
Int J Hematol; 2021 Aug; 114(2):222-227. PubMed ID: 34021850
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
14. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.
Jones C; Levy Y; Tong AW
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25452296
[TBL] [Abstract][Full Text] [Related]
17. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
20. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
